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Introduction
The causal relationship between cigarette smoking and 
a large number of cancers as well as other diseases, par-
ticularly cardiovascular disease and chronic obstructive 
pulmonary  disease  (COPD),  is  well  established,  and 
there  are  no  rational  grounds  on  which  this  relation-
ship  can  be  debated  (U.S.  Department  of  Health  and 
Human Services, 2010). A key aspect of this harm is the 
addictive nature of cigarette smoking, generally thought 
to be primarily caused by the nicotine delivered to the 
smoke. Nicotine addiction is also discussed in detail in 
the 2010 US Surgeon General’s Report referenced above. 
Philip Morris International (PMI) agrees that smoking 
is addictive and that it can be extremely difficult to stop. 
An important question that has been raised concerns the 
alleged possibility that tobacco companies knowingly or 
unknowingly add flavors or other ingredients to their cig-
arettes that increase the addictive properties of cigarette 
smoke (Henningfield et al., 2004). The European Scientific 
Committee  on  Emerging  and  Newly  Identified  Health 
Risks (SCENIHR) has recently evaluated evidence on the 
role of tobacco additives on the addictiveness and attrac-
tiveness of tobacco products (SCENIHR, 2010). Regarding 
addictiveness, the Committee concluded that no tobacco 
additives which are addictive by themselves have so far 
been identified. However, the Committee recommended 
additional  research,  among  others,  to  investigate,  in 
comparable user groups, differences between smokers 
of brands containing additives (in the continental EU) 
and smokers of brands using no additives (in the United 
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Kingdom). A possible approach would be to compare 
cessation rates for smokers of cigarettes with ingredients 
to smokers of those without ingredients, assuming that 
the ease or difficulty of quitting smoking can be taken as 
a measure of cigarette addictiveness. There are currently 
numerous definitions and measures of tobacco addiction 
(see, e.g., US Department of Health and Human Services. 
2010, p. 109–110). It is clear, however, that one measure of 
cigarette addictiveness is the degree of difficulty in smok-
ing cessation (SCENIHR, 2010, p. 82; US Department of 
Health and Human Services, 2010 p. 105–106; Stapleton 
et al, 1995). Therefore, if there exist cigarette types that 
differ significantly in the level of ingredients utilized, a 
comparison of cessation rates in an appropriate setting 
can provide a strong indication of the possible role of 
ingredients with respect to cigarette addictiveness.
Indeed there are two major types of cigarettes world-
wide: flue-cured cigarettes, which use very few ingredients, 
and traditional blended cigarettes, which use a number 
of ingredients. Furthermore, different cigarette markets 
tend to be heavily dominated by one or the other of these 
two cigarette types (e.g., the United Kingdom consumes 
almost exclusively flue-cured cigarettes, whereas the US 
almost exclusively consumes blended ones). Traditional 
blended cigarettes utilize three different types of tobacco −   
flue-cured,  burley,  and  oriental  −  that  are  blended 
together  during  the  manufacturing  process,  whereas 
flue-cured  cigarettes  contain  only  flue-cured  tobacco. 
Flue-cured tobacco is cured over a generally short period 
of time at elevated temperatures, while burley and ori-
ental tobaccos are cured at ambient temperatures dur-
ing a period of about 6 weeks. A major consequence of 
the difference in curing practices for these two types of 
tobaccos is that the elevated temperatures used in flue-
curing rapidly denature the enzymes in tobacco respon-
sible for sugar metabolism leaving the tobacco with high 
sugar  levels,  whereas  these  sugars  are  lost  during  the 
curing of burley tobaccos. In addition to differences in 
curing regimens, burley and oriental tobaccos are geneti-
cally different both from each other and from flue-cured 
tobacco. These distinctions are responsible for somewhat 
different profiles in both the chemical constituents of the 
tobacco and the smoke constituents when the tobaccos 
are burned (Davis and Nielsen, 2007).
As indicated above, the difference between flue-cured 
and traditional blended cigarettes, crucial to the subject 
of this paper, is the fact that flue-cured cigarettes gener-
ally contain no flavoring ingredients, although a small 
number of substances may be added as humectants and 
processing aids, whereas traditional blended cigarettes do 
use a number of different types of ingredients. One coun-
try which consumes almost exclusively flue-cured ciga-
rettes is the United Kingdom. A representative of British 
American Tobacco testified to the Select Committee on 
Health of the UK Houses of Parliament that only six ingre-
dients were used in most of the cigarettes they manufac-
tured for sale in the United Kingdom (Select Committee 
on Health of the UK Houses of Parliament, 2000). Further 
confirmation of the fact that limited ingredients are used 
in flue-cured cigarettes, at least in the United Kingdom, 
can be found in a recent EU Report, which states that 
42% of cigarettes sold in the United Kingdom contain 
no additives, while 48% of cigarettes contain 10 or fewer 
additives (SCENIHR, 2010, p. 76). Moreover, nine of the 
top ten brands sold in the United Kingdom in 2010 (ASH, 
2011) are flue-cured cigarettes. These nine brands do not 
contain any casing and flavoring ingredients, according to 
the information posted on the manufacturers’ websites. 
(Casings are ingredients added during the leaf process-
ing to improve the basic tobacco taste, processing ability 
and moisture-holding capacity (European Commission 
Health & Consumer Protection Directorate, 2007)).
Manufactured traditional blended cigarettes contain 
a number of different types of ingredients, including a 
mixture of flavors, although each flavor makes up a very 
small percentage of the total cigarette by weight. PMI lists 
all ingredients added to cigarettes sold in 92 different 
countries by both country and specific product (http://
www.pmintl-technical-product-information.com/
pages/eng/default/aspx).  Other  manufacturers  publish 
similar lists for their own brands on their own websites. 
Country-specific  data  provide  maximum  use  levels, 
whereas specific product data include the actual level 
of major ingredients. For example, major ingredients in 
the German Marlboro Red Box include humectants, such 
as glycerol (1.7%) and propylene glycol (1.3%); casings, 
such as sugars (sucrose and/or invert sugar, 3.2%), cocoa 
and cocoa products (0.085%), licorice extract (0.4%), and 
carob bean and/or extract (0.071%), and binders, such as 
guar gum (0.3%). In addition, the total amount of natural 
and artificial flavors used in the German Marlboro con-
sists of only 0.004% by weight, and this includes approxi-
mately 20 different substances. The one flavor for which 
the  exact  level  is  specified  is  menthol.  Full-flavored 
Marlboro menthol in Germany contains 0.4% menthol 
by weight. Although blended cigarettes differ in terms 
of the exact recipe of ingredients used, both among dif-
ferent countries and among different brands within the 
same country, the quantitative differences are minor, at 
least with respect to cigarettes manufactured by the large 
multinational cigarette companies, which comprises the 
great  majority  of  cigarettes  marketed  in  the  countries 
considered in this paper.
The difference in the use of ingredients by these two 
types of cigarettes was recently used by Lee et al. (2009) 
to compare mortality rates from lung cancer and COPD 
in four countries in which traditional blended cigarettes 
are  essentially  exclusively  smoked  (Austria,  Denmark, 
Germany, and the United States) and three countries in 
which flue-cured cigarettes are almost exclusively smoked 
(Australia, Canada, and the United Kingdom). The con-
clusion of this paper was that, “differences between coun-
tries in the rates of two major diseases for which smoking 
is  clearly  the  predominant  cause  cannot  materially  be 
explained by whether the cigarettes usually smoked in the 
countries (now and in the past) are flue-cured or blended.” Cigarette ingredients and addictiveness  229
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At the time some preliminary analyses were performed 
to look at cessation rates comparing flue-cured and tra-
ditional  blended  countries.  No  statistically  significant 
differences were found between these two groups based 
on average population-based cessation rates. It was also 
observed, however, that there was a broad range of ces-
sation rates within each group, and it was clear that the 
group  comparisons  could  not  have  been  particularly 
robust due to this large variation.
An improved approach would be to use data derived 
from randomized clinical trials evaluating some type of 
smoking cessation intervention. Not only, in principle, 
are all of the people who enroll in such a study com-
mitted to stop smoking to at least some degree, but the 
extent  to  which  individuals  actually  manage  to  stop 
smoking is well documented. Stead et al. (2008) recently 
published a meta-analysis of 132 clinical trials involv-
ing the use of nicotine replacement therapy (NRT) with 
respect  to  its  effectiveness  on  smoking  cessation.  Of 
these 132 studies, approximately 110 were published in 
countries where blended cigarettes are smoked, while 
20  originated  from  countries  where  flue-cured  ciga-
rettes are smoked. As a consequence, a comparison of 
quit rates derived from such studies should be able to 
determine if smokers of cigarettes with added ingredi-
ents are less likely to quit smoking compared to smok-
ers of cigarettes that contain only very limited added 
ingredients and no added flavors whatsoever; therefore, 
the setting of a randomized clinical trial would allow the 
assessment of the impact of the use of ingredients on 
a smoker’s ability to quit and by implication the addic-
tiveness of the type of cigarette smoked.
Methods
Selection of data sets
The goal of this analysis was to compare cessation rates 
for smokers of cigarettes containing added ingredients, 
including flavors (blended) to those containing few or no 
ingredients and no flavors (flue-cured), who participated 
in randomized clinical trials evaluating the effectiveness 
of  NRT  intervention.  Therefore,  initially  all  such  ran-
domized clinical trials should serve as the basis of the 
data sets to be included. It was assumed that all studies 
published prior to 2007 were identified in the Stead et al. 
review, and these studies were supplemented by a litera-
ture search focused on identifying additional trials that 
had been published subsequent to the Stead et al. review 
(2008). Data sets contained in the review were excluded 
from  further  analysis  if  they  had  any  of  the  following 
characteristics, which were likely to bias the results:
Data sets in which the subjects did not volunteer.  1. 
The reason for that was to ensure that only indi-
viduals who demonstrated a commitment to quit 
smoking were included. Therefore, data sets, for 
example,  in  which  individuals  were  enrolled  by 
their physician were excluded.
Data sets in which mentally ill subjects were pre- 2. 
selected  given  that  their  ability  to  stop  smoking 
may  be  significantly  different  from  individuals 
without mental impairment.
Data sets in which no biochemical validation of  3. 
smoking  cessation  was  conducted.  It  has  been 
known  for  a  considerable  period  of  time  that 
self-reported quit status is often exaggerated. For 
example, Stookey et al. (1987) reported that of the 
102  self-reported  proclaimed  quitters  participat-
ing in a clinical trial to evaluate smoking cessation 
methods, validation by exhaled CO2 confirmed only 
74% of the self-reported quitting status, whereas 
salivary cotinine confirmed only 55%. The misrep-
resentation of smoking cessation is also confirmed 
by a number of studies that were included in the 
Stead et al. data set, such as Hilberink et al. (2010) 
and Hays et al. (1999). As a consequence, combin-
ing studies that used both types of data could intro-
duce a considerable bias.
Data sets that were conducted outside of Europe,  4. 
the United States, or the four flue-cured countries 
(Australia, Canada, New Zealand, and the United 
Kingdom).
Data  sets  that  used  any  type  of  pharmaceutical  5. 
intervention,  such  as  bupropion  or  varenicline. 
The effectiveness of this type of intervention would 
appear to be significantly better than any form of 
NRT;  therefore,  inclusion  of  these  studies  could 
bias the results.
Data sets that did not compare a NRT interven- 6. 
tion group with an untreated control group or data 
sets in which there were differences between the 
intervention group and the control group besides 
NRT. Since one of the types of analysis used in this 
report  was  meta-analysis  on  NRT  effectiveness, 
studies without an appropriate control group can-
not be used.
Multicenter data sets where the subjects were cho- 7. 
sen from different countries some of which were 
blended countries and some of which were flue-
cured countries.
Data sets that did not report the level of smoking  8. 
cessation  for  a  period  of  at  least  24  weeks.  The 
rationale was that, since smoking cessation rates 
in such studies will generally decrease over time, 
including  studies  that  determined  these  rates  at 
only very short time periods would clearly bias the 
results.  For  similar  reasons,  results  available  for 
periods of longer than 16 months were not used.
Data sets that did not report the data for the total  9. 
sample, such as data sets that stratified subjects on 
the basis of, for example, smoking intensity, but 
reported results for only heavy smokers.
Any data set that did not define the type of absti- 10. 
nence,  namely,  sustained  abstinence  or  point 
prevalence.
Data sets for which cessation was not the endpoint. 11. 230  E. Sanders et al.
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 In  order  to  identify  further  data  sets  published  after 
the Stead et al. review, a thorough search of both the 
Cochrane data base and MEDLINE was made using the 
keywords  “nicotine  replacement  therapy,”  “NRT,”  and 
“smoking cessation” from 2006 through July 2010, result-
ing in a total of 54 potentially relevant articles.
Data extraction
Data  were  extracted  from  the  publications  meeting 
the inclusion and exclusion criteria independently by 
two  researchers.  Any  observed  differences  were  then 
resolved. In addition to first author, publication year and 
country where the study was conducted, size of NRT and 
control groups, and number of successful cessations per 
group  were  recorded.  The  study-specific  definition  of 
cessation (sustained versus point prevalence), and the 
period  after  which  abstinence  was  determined  (with 
all periods assigned to the dichotomous variable study 
duration of either 6 or 12 months, and a preference for 
the latter for data sets reporting data for both periods) 
was recorded, as well as type of NRT (gum, patch, loz-
enge, inhaler, and spray) and level of psychological sup-
port. The support level “high” was assigned to data sets 
where more than just reading materials on smoking ces-
sation were distributed to study participants, in which 
case the recorded support level was “low.” Study quality 
ratings, as provided by Stead et al., were also recorded 
and, where data sets were not considered in the Stead 
et  al.  review,  assigned  according  to  the  same  criteria 
(based on effectiveness of randomization procedures as 
well as their description in the publication). Three cat-
egories were adopted, with category A being designated 
when data sets reported allocation procedures in suffi-
cient detail to ensure that treatment status could not be 
known or predicted until a participant was enrolled and 
assigned  to  a  condition;  category  B  being  designated 
when data sets either did not report how randomiza-
tion was performed or reported it in insufficient detail to 
ensure that no selection bias had occurred; and category 
C being designated for data sets that clearly used inferior 
randomization procedures, such as using the day of the 
week in which subjects were enrolled.
Data analysis
Meta-analysis  of  cessation  rates  was  performed  based 
on study-level NRT effect and precision estimates using 
MetaAnalyst  (version  Beta  3.13,  Wallace  et  al.,  2009). 
Since the regression analysis of effects of ingredients on 
cessation rates estimated odds ratios (OR) (see below), 
the meta-analysis of NRT effects on cessation rates was 
also based on OR in order to maintain consistency. Fixed 
effects estimates were obtained using inverse-variance 
weighted aggregation, whereas random effects estimates 
were  calculated  using  the  DerSimonian–Laird  formu-
las (Petitti, 2000). In addition to the overall assessment 
of  intervention  (NRT)  effects,  stratified  analyses  were 
performed regarding type of NRT, cigarette type, defini-
tion of cessation, level of psychological support, study 
decade, study size (≥300 versus <300 study participants), 
study  quality,  and  combinations  of  cigarette  type  and 
definition of cessation. It should be noted that in all the 
analyses conducted that exact date of the study comple-
tion could not be determined, since more than half of the 
publications (56%) provided no relevant information. Of 
those that did provide information, it was usually the date 
at the end of the recruitment or of subject enrolment. 
However, given that there were only very few examples of 
more than about 1 year between the estimated comple-
tion date of the study and its publication, publication 
date can serve as a surrogate for the actual year of the 
study. Heterogeneity was assessed through the I2 statis-
tic, and pairwise comparisons of log-transformed effects 
estimates were assessed using Z-tests based on a testwise 
alpha level of 5%.
Analyses  of  effects  of  ingredients  (i.e.,  cigarette 
type)  were  conducted  by  means  of  logistic  regression 
of  cessation  rates  using  SAS  (version  9.1).  To  identify 
relevant  main  effects,  the  following  potential  predic-
tor variables were considered in forward selection and 
backward elimination stepwise multiple logistic regres-
sion analyses with a testwise alpha level of 5%: cigarette 
type (blended versus flue-cured as reference, the latter 
based on findings from Australia, Canada, New Zealand, 
and the United Kingdom), study size (≥150 versus <150 
subjects), study duration (6 versus 12 months), level of 
psychological support (high versus low), type of absti-
nence (sustained versus point prevalence), study decade 
(with  the  three  periods  of  1980–1989,  1990–1999,  and 
2000–2010), and study quality (A, B, or C, as described 
above). Based on the identified main effects model, for 
which adjusted OR were calculated in both control and 
treatment  groups  data  sets  separately,  screening  for 
interactions was undertaken in control group data. The 
interaction screening was restricted to the control group 
to eliminate the potential effect of NRT, which should 
in  principle  lead  to  a  simpler  interpretation  of  those 
interactions  that  are  found.  Stepwise  multiple  logistic 
regressions (both forward and backward) with all main 
effects variables and all bivariate interaction terms were 
undertaken. According to the interaction structure of the 
final interaction model, effects estimates and confidence 
intervals based on the covariance matrix were calculated 
for both predictors participating in a particular interac-
tion, each at the reference level of the other, as well as 
for  the  non-reference  level(s)  of  the  predictor  of  pri-
mary interest at the non-reference level(s) of the other 
predictor  involved  in  the  interaction.  For  control  and 
treatment  group  data  combined,  conditional  multiple 
logistic regression analysis based on the identified main 
effects  model  and  additionally  including  an  indicator 
variable for group (with control group as reference) was 
performed, taking into account the clustering of pairs of 
cessation rates within studies.
Classification tree analysis (CTA) (Biggs et al., 1991) in 
conjunction with main effect and interaction plots were 
used to identify high-order interactions and to display Cigarette ingredients and addictiveness  231
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them  in  easily  interpretable  diagrams.  Chi-square  5% 
alpha level tests were used to split the control data set.
Results
Studies used in the analysis
Application of the stated exclusion criteria was carried 
out on both those data sets considered by Stead et al., 
and the 54 papers identified through searching the litera-
ture following the publication of this review. Of the 130 
publications (133 data sets) identified as being relevant 
by Stead et al., 53 (54 data sets) were eliminated as a 
consequence of the above exclusion criteria. Specifically, 
one publication was eliminated as a consequence of cri-
terion 1; 1 as a consequence of criterion 2; 19 as a conse-
quence of criterion 3; 7 as a consequence of criterion 4; 
3 as a consequence of criterion 5; 18 as a consequence of 
criterion 6; 3 as a consequence of criterion 7; and 1 as a 
consequence of criterion 8. It should be noted that data 
sets from 16 of these publications were not included by 
Stead et al., in their main analysis that assessed the effect 
of NRT treatment on smoking cessation. In addition, the 
publications by Dautzenberg (2001) and Kralikova et al. 
(2002) were not used, because the results were drawn 
from abstracts and, in both cases, the results were later 
published in their entirety. Therefore, of the 133 data sets 
utilized by Stead et al., a total of 56 were excluded leaving 
76 data sets. A number of these data sets described two 
independent trials. These were not treated independently 
by Stead et al., but were treated independently in this 
analysis. As a consequence, the total number of data sets 
utilized that were drawn from Stead et al. was 91. Of the 
54 possibly relevant studies identified by searching the 
recent literature, 43 were rejected based on the defined 
exclusion criteria as follows: 3 publications were rejected 
as a consequence of criterion 2; 10 as a consequence of 
criterion 3; 4 as a consequence of criterion 4; 2 as a con-
sequence of criterion 5; 11 as a consequence of criterion 
6; 1 as a consequence of criterion 7; 5 as a consequence 
of criterion 8; 1 as a consequence of criterion 9; and 4 as 
a consequence of criterion 11. In addition, two of these 
papers were follow-up publications to data sets that had 
been previously included. Of these additional data sets, 
three of them, studies by Okuyemi et al. (2007), Pollak 
et al. (2007), and Rennard et al. (2006) were not included 
in the Stead et al. analysis but were mentioned in the list 
of data sets excluded from their review. No reasons were 
given as to why these data sets were excluded. Lastly, 
the  Dautzenberg  (2007)  and  Kralikova  (2009)  papers 
replaced the abstracts utilized by Stead et al. Two of these 
11 additional papers were subdivided into two data sets 
each, giving a total of 104 data sets derived from 87 dif-
ferent publications included in this analysis. All rejected 
studies are noted and referenced in the Appendix.
All  of  the  data  sets  used  for  the  meta-analyses  are 
summarized in Table 1. Five different types of NRT were 
used, namely, gum (47 data sets), patch (36 data sets), 
sublingual tablets/lozenges (6 data sets), inhaler (6 data 
sets), and spray (4 data sets). In addition there were five 
data sets that used combinations of NRT. Twenty data 
sets were conducted in countries where the vast majority 
of cigarettes smoked utilize minimal added ingredients 
(flue-cured). Of these data sets, 14 were from the United 
Kingdom,  3  from  Australia,  2  from  New  Zealand,  and 
1 from Canada. The remaining 84 data sets were from 
countries  where  cigarettes  contain  added  ingredients 
(blended). A total of 54 data sets were from the United 
States, and the remaining 30 studies were from Europe. 
The  European  studies  include  seven  from  Sweden, 
six from Denmark, three from Croatia, two each from 
Belgium, Iceland, Italy, Spain, and Switzerland, and one 
each from the Czech Republic, Finland, France, and the 
Netherlands. The majority of the data sets were small, 
with 72 containing less than 300 subjects. There was no 
single study that made an unusually large contribution 
to the pooled results, with the largest study (ICRF, 1994, 
study 93), which had 842 treated subjects and 844 con-
trols, contributing only 0.8% to the total sample. There are 
numerous other differences among the studies, and these 
will be discussed in greater detail in the next sections.
For the logistic regression analysis of cessation rates, 
the analysis was conducted independently on the treat-
ment groups and the control groups. The number of data 
sets used was slightly greater than the list shown in Table 
1. The reason for this is that there were some treatment 
groups  in  the  publications  listed  in  Table  1  for  which 
there was no separate corresponding control group, and 
some control groups for which there was no correspond-
ing treatment group. Although these groups could not be 
included in the meta-analysis, they could be and were 
included in the logistic regression. In addition, it should 
be noted that, in some cases, a control group was used as 
the comparison for two treatment groups, in which case it 
was considered only once in the multiple logistic regres-
sion analysis. A total of five additional treatment data sets 
were included in the multiple logistic regression analy-
sis, whereas one data set was not analyzed giving a final 
number of 108. These data sets are listed in Table 2 (A and 
B). A total of 10 additional control data sets were included 
in the multiple logistic regression analysis, whereas six 
data sets were not analyzed giving a final number of 108. 
These data sets are listed in Table 2 (C and D).
Effect of NRT
Although not the primary focus of the present study, the 
results of this analysis should clearly demonstrate a posi-
tive effect of NRT intervention to confirm that the selec-
tion of the data sets shown in Table 1 still correspond to 
the data sets used by Stead, et al. This is indeed the case. 
When  the  total  data  set  was  analyzed,  the  pooled  OR 
comparing smoking cessation rates for treated subjects 
and for control subjects was 1.70 (95% CI, 1.58–1.82) by 
fixed effects meta-analysis and 1.76 (95% CI, 1.61-1.93) 
by random effects meta-analysis (Table 3). As there is 
heterogeneity in this pooled OR, as demonstrated by the 
I2 value (p = 0.006 on 103 degrees of freedom) (Higgins 232  E. Sanders et al.
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et al., 2003), and in many of the ORs estimated in the 
stratified analyses as well, conclusions drawn from these 
meta-analyses will be based on the random-effects esti-
mates, although pooled estimates using both fixed and 
random effects methods for all comparisons are listed in 
Table 3. The pooled ORs for NRT intervention are some-
what higher than the estimate of 1.58 (95% CI, 1.50–1.66) 
reported by Stead et al., from which many of the data 
sets used in this analysis were drawn. The Stead et al. 
estimate, however, was based on pooled risk ratios using 
Mantel–Haenzel  methodology.  Using  the  exact  same 
methodology, the pooled fixed effects estimate for NRT 
intervention of the 104 data sets used here was 1.58 (95% 
CI, 1.49–1.68), which is identical to that reported in the 
review. This result clearly indicates that NRT does indeed 
improve  individuals’  ability  to  quit  smoking,  at  least 
under the conditions of a clinical trial, and also clearly 
demonstrates that the data set used to address the com-
parisons made in this analysis is representative.
An  important  comparison,  particularly  from  the 
standpoint  of  this  analysis,  is  the  effect  of  NRT  inter-
vention between countries in which blended cigarettes 
(contains added ingredients) are primarily smoked com-
pared to countries in which flue-cured cigarettes (no or 
few  added  ingredients)  are  primarily  smoked.  For  the 
84 studies reported from the United States and Europe 
excluding the United Kingdom (blended cigarettes), the 
pooled random effects OR estimate was 1.80 (95% CI, 
1.63–1.98), while the pooled random effects OR estimate 
for flue-cured countries was 1.61 (95% CI, 1.27–2.04). The 
estimate for blended cigarettes did not indicate heteroge-
neity, with p = 0.066 on 83 degrees of freedom. However, 
the  results  for  flue-cured  countries  remained  hetero-
geneous, with p = 0.007 on 19 degrees of freedom. This 
comparison suggests that NRT intervention in smokers 
of cigarettes containing ingredients may be about 12% 
more efficacious than in smokers of cigarettes containing 
minimal ingredients, although this difference is clearly 
not statistically significant (p = 0.39).
Table 3 contains the results obtained from stratifica-
tion of intervention effects estimates, according to other 
variables  that  were  extracted  from  the  publications. 
Always compared to the respective reference category, 
the  results  indicate  larger  NRT  effects  in  data  sets  in 
which results were reported after 6 months as opposed 
to 1 year, when sustained abstinence is considered (both 
overall as well as when types of cigarettes were consid-
ered separately), when support was low, when the study 
was conducted before or after 1990–1999, and when study 
quality was A or B. With respect to the efficacy of the dif-
ferent types of NRT, the lowest pooled OR is for nicotine 
gum, with increasing effectiveness being associated with 
Table 3.  Estimates of treatment effects on cessation rates, overall as well as stratified by type of NRT, type of cigarette, study duration, type 
of abstinence, level of support, study decade, study size, study quality, as well as combined strata, regarding type of cigarette and type of 
abstinence.
Description No. of studies
Fixed effects pooled  
OR (95% CI)
Random effects pooled  
OR (95% CI) I2 Degrees of freedom p
All studies 104 1.70 (1.58–1.82) 1.76 (1.61−1.93) 0.28 103.00 0.006
Nicotine gum 47 1.52 (1.38–1.69) 1.61 (1.39−1.86) 0.44 46.00 0.001
Nicotine patch 36 1.80 (1.59−2.04) 1.81 (1.59−2.06) 0.05 35.00 0.383
Nicotine tablets/lozenge 6 1.95 (1.39−2.74) 1.95 (1.39−2.74) 0.00 5.00 0.722
Nicotine inhaler 6 2.30 (1.65−3.21) 2.30 (1.65−3.21) 0.00 5.00 0.784
Nicotine spray 4 2.34 (1.62−3.34) 2.34 (1.62−3.34) 0.00 3.00 0.789
Blended countries 84 1.75 (1.61−1.90) 1.80 (1.63−1.98) 0.20 83.00 0.066
Flue-cured countries 20 1.53 (1.31−1.79) 1.61 (1.27−2.04) 0.50 19.00 0.007
1-year cessation data 73 1.66 (1.52−1.80) 1.71 (1.54−1.90) 0.24 72.00 0.037
6-month cessation data 31 1.81 (1.58−2.08) 1.91 (1.59−2.30) 0.36 30.00 0.025
Sustained abstinence 72 1.94 (1.78−2.12) 1.96 (1.78−2.16) 0.14 71.00 0.16
Point prevalence 32 1.30 (1.15−1.48) 1.32 (1.15−1.51) 0.09 31.00 0.322
High support 73 1.69 (1.55−1.84) 1.73 (1.57−1.91) 0.22 72.00 0.051
Low support 30 1.72 (1.49−1.98) 1.88 (1.53−2.30) 0.42 29.00 0.009
Studies, 1980–1989 24 1.70 (1.44−2.02) 1.82 (1.45−2.28) 0.37 23.00 0.037
Studies, 1990–1999 46 1.64 (1.48−1.80) 1.68 (1.49−1.90) 0.30 45.00 0.029
Studies, 2000–2010 34 1.83 (1.59−2.12) 1.88 (1.60−2.22) 0.18 33.00 0.183
>300 subjects 32 1.57 (1.42−1.74) 1.64 (1.42−1.89) 0.47 31.00 0.002
<300 subjects 72 1.84 (1.66−2.05) 1.86 (1.67−2.08) 0.11 71.00 0.227
Quality A 26 1.73 (1.52−1.98) 1.79 (1.52−2.11) 0.28 25.00 0.091
Quality B 70 1.71 (1.56−1.88) 1.80 (1.60−2.02) 0.31 69.00 0.009
Quality C 8 1.51 (1.18−1.94) 1.51 (1.17−1.95) 0.03 7.00 0.403
Blended and SA 55 2.03 (1.82−2.25) 2.04 (1.82−2.27) 0.08 54.00 0.315
Blended and PP 29 1.38 (1.21−1.57) 1.38 (1.21−1.57) 0.00 28.00 0.647
Flue cured and SA 17 1.74 (1.47−2.06) 1.75 (1.42−2.16) 0.27 16.00 0.145
Flue cured and PP 3 0.79 (0.54−1.17) 0.85 (0.52−1.38) 0.15 2.00 0.308Cigarette ingredients and addictiveness  237
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the  nicotine  patch,  nicotine  tablet/lozenge,  nicotine 
inhaler, and nicotine spray. Only the difference between 
nicotine spray and nicotine gum is statistically significant 
(p = 0.03).
Cessation rates in blended versus flue-cured countries
Model selection based on both forward and backward 
selection  through  stepwise  logistic  regression,  carried 
out in control group data, resulted in study duration and 
study quality not being retained in the final main effects 
model. The final main effects model contained the vari-
ables cigarette type (blended versus flue-cured as refer-
ence), cessation type (sustained abstinence versus point 
prevalence as reference), support (high versus low psy-
chological support as reference), decade (ordinal with 
levels 0, 1, and 2 representing the periods 1980–1989, 
1990–1999, and 2000–2010, respectively), and study size 
(≥150 versus <150 as reference). Screening for bivariate 
interactions among the variables contained in the final 
main effects model resulted, in both forward and back-
ward selection, in the following four additional interac-
tion terms being retained in the final model: cigarette 
type versus support, cigarette type versus decade, study 
size versus decade, and study size versus cessation type. 
To account for the effect of study decade on cessation 
rates not being linear, the ordinal variable was replaced 
by a pair of dummy variables with period 1980–1989 as 
reference.  Table  4  contains  the  effect  estimates  of  the 
main effects model, as well as of the interaction model 
for the control group data. To facilitate assessing the sta-
bility of the estimates based on the main effects model, 
they were also calculated for the treatment group data.
As the effect estimates of the main effects model using 
control  group  data  demonstrate,  cessation  rates  were 
about  30%  higher  in  countries  where  predominantly 
blended cigarettes (ingredients) were smoked, as com-
pared to countries where predominantly flue-cured ciga-
rettes (limited ingredients) were smoked. Cessation rates 
were lower by a factor of two when determined through 
sustained abstinence, as compared to point prevalence. 
High  levels  of  psychological  support  were  associated 
with an almost 140% increase of the chances of success-
ful cessation, compared to low support levels. Compared 
to the 1980–1989 period, chances of successful cessation 
were reduced by about 70% compared to the 1990–1999 
decade and by more than a factor of two compared to the 
most recent decade. In larger data sets, the probability of 
cessation was about 40% lower than in smaller data sets.
Overall, this pattern of effects of the variables of the 
main effects model was replicated in the treatment group 
data set. While, here, the effect related to cigarette type 
was more pronounced (OR 1.90 for treatment group com-
pared to OR 1.32 in the control group), the cessation type 
(sustained versus point prevalence cessation) as well as 
the level of psychological support was of somewhat less 
importance. The estimates related to study period and 
study size were essentially equivalent to those obtained 
in the control group data.
The interaction structure identified by screening for 
bivariate interactions poses considerable restrictions on 
what effects can be estimated in a meaningful way, which 
implies a rather complicated pattern of effect estimates. 
It needs to be noted that assessing the estimates obtained 
for the interaction model is conditional to the restric-
tions as contained in Table 4, since estimates are either 
conditional to reference levels or may imply effect modi-
fication by other variables, or a combination of both. In 
low psychological support data sets, cessation rates were 
higher by almost 250% in countries where predominantly 
blended cigarettes as compared to flue-cured cigarettes 
were smoked, and in the decade of 1980–1989, whereas 
(in the same decade) the excess was less than half that 
size under conditions of high psychological support. The 
profound excess cessation rates in the 1980–1989 decade 
in blended countries, observed in data sets with low psy-
chological support, declined through decades 1990–1999 
Table 4.  Effect estimates and 95% CI based on the main effects model in control and treatment group data. Effect estimates of the 
interaction model are given for the control group data on the right half, indicating the scope of applications of estimates (population 
restrictions), according to the interaction structure of the model. In the effect column, the exposure category is mentioned.
Main effects model  Interaction model 
Effect OR 95% CI Effect Population restrictions OR 95% CI
Data: Control groups Data: Control groups    
  Blended cigarettes 1.32 1.14–1.53 Blended cigarettes Low support and 1980–1989 3.47 2.20–5.45
  Sustained abstinence 0.49 0.44–0.55 Blended cigarettes Low support and 1990–1999 1.52 0.95–2.42
  High support 2.38 2.06–2.75 Blended cigarettes Low support and 2000–2010 1.05 0.39–2.82
  1990–1999 0.58 0.50–0.69 Blended cigarettes High support and 1980–1989 2.12 1.41–3.20
  2000–2010 0.42 0.35–0.50 Large study Point prevalence and 1980–1989 2.19 1.39–3.44
  Large study 0.71 0.63–0.80 Large study Point prevalence and 1990–1999 1.04 0.84–1.30
Data: Treatment groups Large study Point prevalence and 2000–2010 1.26 0.96–1.65
  Blended cigarettes 1.90 1.70–2.13 Large study Sustained abstinence and 1980–1989 0.97 0.62–1.52
  Sustained abstinence 0.89 0.81–0.98 High support Flue-cured cigarettes 3.22 2.12–4.88
  High support 2.02 1.82–2.25 1990−1999 Flue-cured cigarettes and small study 1.18 0.77–1.80
  1990–1999 0.62 0.55–0.70 2000–2010 Flue-cured cigarettes and small study 1.16 0.71–1.87
  2000–2010 0.45 0.39–0.51 Sustained abstinence Small study 0.70 0.58–0.83
  Large study 0.73 0.66–0.80        238  E. Sanders et al.
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and 2000–2010, with no substantial difference left for the 
most recent decade. Restricted to data sets in countries in 
which predominantly flue-cured cigarettes are smoked, 
high levels of psychological support were associated with 
increased cessation rates by about 220%, compared to 
low support levels. Decade per se did not seem to have an 
impact on cessation rates in flue-cured countries based 
on results from small studies.
Restricted to point prevalence data, large study size did 
not have an impact on cessation rates in the 1990–1999 
and  2000–2010  decades,  compared  to  the  1980–1989 
decade,  where  cessation  rates  in  large  data  sets  were 
higher by almost 120% compared to small studies. No 
effect of study size on cessation rates was observed in 
the 1980–1989 decade when the outcome was sustained 
abstinence. When assessed in small data sets, sustained 
cessation rates were lower by about 30% as compared to 
point prevalence rates.
A combined analysis of control and treatment groups 
data  was  undertaken  by  means  of  conditional  logis-
tic  regression  based  on  the  main  effects  model,  with 
study number as strata and a variable indicating type 
of group (treatment versus control). The obtained treat-
ment effect, that is, adjusted for all variables of the main 
effects model as contained in Table 4 was 1.77 (95% CI: 
1.60–1.96),  indicating  a  77%  increased  cessation  odds 
under nicotine replacement treatment, as compared to 
control group conditions. The estimates obtained for the 
variables of the main effects model were very close to 
those contained in Table 4: 1.85 (1.45–2.37) for blended 
cigarettes, 0.79 (0.63–0.99) for sustained abstinence, 2.11 
(1.64–2.73) for high support, 0.56 (0.44–0.71) for period 
1990–1999,  0.44  (0.33–0.57)  for  period  2000–2010,  and 
0.84 (0.67–1.04) for large study size.
Lastly, to explore the effects of different types of nico-
tine replacement therapies, the analysis of the treatment 
group data set was repeated by adding a set of reference-
coded dummy variables to the main effects model, which 
coded  different  types  of  nicotine  replacement  against 
nicotine spray as reference. The estimates of the main 
effects model variables changed by <3%, except for the 
1990–1999 period effect, which was 0.66 (data not shown) 
instead of 0.62, as shown in Table 4. The OR were 0.93, 
0.82, 0.95, and 0.87 for gum, patch, lozenge, and inhaler, 
respectively,  indicating  somewhat  lower  effects  for  all 
four NRTs compared to nicotine spray, but with 95% con-
fidence intervals including unity.
Because of the complexity of the interaction structure 
that was obtained when using stepwise logistic regres-
sion, it was decided to also analyze the data using a CTA 
approach to see if a simpler picture emerged. Only two 
factors were found to be differentiated when this analy-
sis was applied to the control group, namely, the study 
size,  and  the  level  of  support.  The  results  for  level  of 
support was found to be significantly differentiated in 
the CTA, with quitting being higher in data sets where 
subjects received a high level of psychological support 
(14%) than in those where subjects received a low level of 
support (8%), which was in line with the multiple logis-
tic  regression  analysis.  Also  consistent  with  the  main 
effects  logistic  regression  model  was  the  fact  that  the 
quit fraction was statistically higher in small data sets 
(>150, 13%) than in large data sets (<150, 9%). No differ-
ence in cessation rates was detected between smokers in 
blended  countries  (ingredients)  compared  to  smokers 
in flue-cured countries (few or no ingredients). In addi-
tion, there was no difference in quit rates with respect to 
whether results were reported by sustained abstinence 
or point prevalence. Both of these results are in contrast 
with  the  multiple  logistic  regression  results.  Although 
there was no effect of decade, there was an interaction 
between decade, study size and level of support. Figure 1  
shows a plot of the relationship between data sets with 
high support and those with low support plotted as a 
function of decade for both small data sets and large data 
sets. As shown in the figure, the difference in cessation 
rates between small data sets with high and low support 
was statistically different only between 1980 and 1989. 
The difference narrowed considerably in the following 
decade, and in the 2000–2010 decade, there was essen-
tially no difference as a function of level of support.
Discussion
Quitting rates in countries with added ingredients 
(blended) and those with few added ingredients  
(flue-cured)
The main analysis reported here has looked at 108 data 
sets  derived  from  similar  control  groups  from  clinical 
trials on NRT performed over the last three decades in 
seven different countries. If the use of ingredients would 
have increased the addictiveness of cigarettes, a lower 
success rate for cessation in these trials would have been 
expected in the countries where the addition of ingredi-
ents to cigarettes predominates (i.e., in blended markets). 
This was clearly not the case for the analysis reported 
here. The results of the main effect model obtained from 
multiple logistic regression analysis of the 108 data sets 
indicate  that  cessation  rates  were  generally  higher  in 
countries with cigarette ingredients (blended) than those 
with limited or no ingredients (flue-cured). Although this 
finding seems to be fairly robust, in that it is also reflected 
in a similar group of data sets derived from the treatment 
groups,  and  remains  significant  through  a  number  of 
interaction models as well, it would seem implausible to 
suggest that it is the presence of ingredients that make it 
easier to quit. It is, however, clear that the data reported 
here do not in any way support the suggestion that ingre-
dients could increase the addictiveness of cigarettes.
A number of variables were identified as influencing 
cessation rates as shown in Table 4. Trials with high psy-
chological/behavioral  support  were  significantly  more 
successful  in  leading  to  smoking  cessation  than  were 
trials with low support. This difference is larger in the 
control group than in the NRT group, possibly because 
the individuals in the intervention group benefited from Cigarette ingredients and addictiveness  239
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both NRT and the presence of psychological or behavioral 
support, although the difference did not reach statisti-
cal significance at the 5% level (p = 0.09). Small data sets 
reported a greater extent of smoking cessation than did 
large data sets, and this result was statistically significant 
for both the treatment and the control groups in the main 
effects model. This difference may well reflect an effect 
of  more  focused  psychological  support:  individuals  in 
small data sets are more likely to receive individual atten-
tion than individuals in large data sets. The results for the 
method of reporting cessation, sustained abstinence, or 
point  prevalence,  are  completely  in  line  with  expecta-
tions, in that reported cessation rates were lower when 
sustained abstinence was reported than when point prev-
alence was used. It is important to note, as it is detailed 
in Table 4, that the adjusted OR for sustained abstinence 
with respect to point prevalence in the NRT group was 
0.89 (95% CI, 0.81–0.98), whereas for the control group 
the OR was 0.49 (95% CI, 0.44–0.55). This difference is sta-
tistically significant (p = 3.3 × 10−15). Why such a difference 
emerged between the NRT group and the control group 
with respect to reporting method is certainly not obvious.
Considering  that  all  the  trials  were  conducted 
between 1980 and 2010, it seemed logical to divide the 
data sets into three time periods, namely 1980–1989 (24 
data sets), 1990–1999 (46 data sets), and 2000–2010 (34 
data sets). Therefore, decade is a ternary variable, while 
all the other variables are binary. For both the treatment 
and control group cessation rates declined as a function 
of decade. The result shown in Table 4 can be interpreted 
as a decrease by about a factor of 2.4 in cessation rates 
when  moving  from  the  1980s  through  the  1990s,  and 
then to the first 11 years of the 21st century. This finding 
would appear to be counter-intuitive. During this 30-year 
period, there has been an increase in both external pres-
sures to quit smoking and in public smoking bans in all 
countries included in this analysis. As a consequence, 
it might be anticipated that cessation rates should have 
increased during this period of time, yet the opposite is 
true, at least in the setting of a randomized clinical trial 
to evaluate NRT. On the other hand, this result appears 
to be in line with population-based survey data suggest-
ing that individuals who continue to smoke are far more 
refractory than those who have already quit. A quotation 
from NCI Smoking and Tobacco Control Monograph 15 
(US Department of Health and Human Services, 2003) 
clearly supports this.
The fraction of those who have ever smoked but have suc-
cessfully quit increased dramatically over the last half-
century to the point at which approximately one-half of 
those who have ever smoked are currently former smok-
ers. However, declines in per capita consumption slowed 
dramatically during the middle of the 1990s, and the CPS 
data show a decline in cessation attempts and abstinence 
between the 1992/93 and 1995/96 surveys (see Chapter 
8). These observations raise a concern that those smok-
ers who could easily quit, or who could be influenced by 
existing tobacco control approaches to quit, have done 
so, leaving behind a residual population of smokers who 
are more heavily addicted and who need new or more 
individualized cessation interventions.
A number of statistically significant interactions were 
identified in the stepwise logistic regression analysis, two 
of which involved decade (Table 4). Of particular note is 
the observation that the higher quit rates for smokers of 
Figure 1.  In small studies (left panel), studies with high support resulted in increased levels of smoking cessation as compared to studies 
with low support in decade 1. The difference in smoking cessation rates as a function of support declined in the 1990s (decade 2) and 2000s 
(decade 3). In large studies (right panel), there was a significant effect of high support in studies conducted in the 2000s but not in studies 
conducted in the 1990s. (See colour version of this figure online at www.informahealthcare.com/iht)240  E. Sanders et al.
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blended cigarettes declined during the three decades, so 
that in the 1990–1999 and 2000–2010 intervals, there was 
no longer a statistically significant difference between quit 
rates for smokers of blended cigarettes compared to smok-
ers of flue-cured cigarettes; however, this was observed 
only  for  data  sets  characterized  by  low  psychological/
behavioral  support.  A  possible  explanation  is  that  this 
result is simply a consequence of the restrictions imposed 
by the interaction model resulting in a higher influence of 
random variation in the comparisons. This is supported 
by the fact that there are several other interaction terms 
involving decade. For example, although the main effects 
model demonstrates that cessation rates for large data 
sets are statistically lower than those in small data sets, 
cessation rates for large data sets using point prevalence 
as the reporting method were significantly higher in the 
decade 1980–1989. This effect was also seen in the latter 
two decades, although in this case the difference was not 
statistically significant. Likewise, the decrease in cessation 
rate as a function of decade observed in the main effects 
model is not observed in the interaction of decade, flue-
cured cigarettes, and small data sets.
Not  only  did  the  interaction  screening  produce  a 
very  complex  picture  but  it  was  also  observed  that 
small corrections to the data set resulted in noticeable 
changes in the interaction structure. As a consequence, 
the control group data were also investigated using a 
CTA. The advantage of CTA is that a much simpler pic-
ture is produced. In that the data are split in a recursive 
fashion, each split determines what can be split in the 
subsequent stages. Since this process is a one-variable-
at-a-time  analysis,  combinations  of  variables  are  not 
considered during the splitting but rather emerge based 
on the tree structure. This implies that when a certain 
split is undertaken − due to the superior effect size of a 
particular variable at any particular stage − the possibil-
ities to detect interactions further down are very much 
limited. This is also a weakness of CTA, since effects 
that might be detected by a technique, such as multiple 
logistic regression analysis, may not emerge as being 
significant. This issue as well as others is discussed in 
detail in a recent review (Strobl et al., 2009). Indeed, a 
much simpler picture with respect to interactions was 
observed by CTA with only one statistically significant 
interaction,  a  three-way  interaction,  being  observed. 
Cessation  rates  in  small  data  sets  with  high  support 
declined  as  a  function  of  decade  when  compared  to 
small data sets with low support, with no statistically 
significant difference being observed in the most recent 
decade (Figure 1). This is exactly the same pattern that 
was observed using multiple regression analysis with 
respect  to  cessation  rates  of  blended  and  flue-cured 
smokers with low support as a function of decade. This 
CTA interaction result is most probably a consequence 
of random differences with respect to interactions with 
decade, since there is no logical reason that can explain 
why level of support ceased to become important as a 
function of decade.
Perhaps  not  unsurprisingly,  given  the  properties  of 
CTA noted above, only two variables that had a statisti-
cally significant effect on cessation rates were identified 
by this analysis. Cessation rates in studies with a high 
level of psychological support were 80% higher than those 
with a low level of psychological support. This result is in 
agreement  with  the multiple logistic regression analy-
sis, although the magnitude is somewhat less (Table 4). 
Also consistent with the logistic regression analysis, CTA 
showed that cessation rates in small data sets were sig-
nificantly higher than those in large data sets. All other 
factors identified as having an effect on cessation rates 
in the stepwise regression were not differentiated in the 
CTA, including the difference between cessation rates for 
smokers of blended and flue-cured cigarettes. The failure 
to differentiate cessation rates as a function of type of 
cigarette smoked is not surprising, given the lower sen-
sitivity of the CTA approach, particularly given that the 
difference observed by multiple logistic regression analy-
sis, albeit statistically significant, was certainly not large 
(30%). Nevertheless, the finding by CTA clearly does not 
support a conclusion that cessation rates for smokers of 
cigarettes containing few or no ingredients (flue-cured) 
was increased compared to smokers of cigarettes con-
taining multiple ingredients (blended).
Effect of NRT
The meta-analysis conducted on the 104 data sets listed in 
Table 1 clearly indicates that the use of NRT can increase 
cessation rates. Moreover, there is complete agreement 
with the results of this analysis and the analysis carried 
out  by  Stead  et  al.,  as  noted  in  the  “Results”  section. 
Although  this  analysis  found  a  significant  difference 
between  nicotine  spray  and  nicotine  gum,  the  results 
of the logistic regression analysis indicate no statistical 
difference among any of the interventions. This is consis-
tent with the findings of Stead et al., who concluded that, 
“The choice of which form [of NRT] to use should reflect 
patient needs, tolerability, and cost considerations.”
All of the variables that were evaluated as potential 
confounders in the multiple logistic regression analysis 
were  also  tested  by  meta-analysis  (Table  3).  The  level 
of psychological support, which had been shown to be 
a statistically significant predictor of smoking cessation 
rates for both the control and treatment groups by mul-
tiple  logistic  regression  (Table  4),  was  not  statistically 
differentiated in the meta-analysis (p = 0.47), a finding in 
agreement with the conclusions of Stead et al. This lack of 
difference as a function of level of psychological support 
demonstrates that a subgroup analysis within a meta-
analysis designed to measure the effect of one interven-
tion on cessation rates, in this case NRT, does not predict 
cessation rates with respect to differences for other fac-
tors.  As  calculated  by  the  multiple  logistic  regression 
analysis, cessation rates increase by a factor of about two 
when data sets with high support are compared to those 
with  low  support.  However,  because  this  increase  in 
cessation rates occurs to about the same extent for both Cigarette ingredients and addictiveness  241
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treatment and control groups, no statistically significant 
difference is observed in the meta-analysis.
A second interesting meta-analytical result involved 
the type of abstinence reported. A total of 72 data sets 
reported sustained abstinence; that is, continuous absti-
nence since the date that the individual reported having 
stopped smoking. The remaining 32 studies reported ces-
sation by point prevalence. This type of evaluation utilized 
a fixed period of time, usually 1 week, during which a sub-
ject was abstinent just before being evaluated. As a conse-
quence, lapses during which the subject may have been 
smoking were ignored. Therefore, it would be anticipated 
that a greater success of NRT intervention would appear 
to have been obtained when cessation was determined 
by point prevalence, which was clearly demonstrated to 
be the case by logistic regression (Table 4). However, the 
pooled random effects OR for sustained abstinence of 
1.96 (95% CI, 1.78–2.16) is clearly significantly larger than 
the pooled random effects OR of 1.32 (95% CI, 1.15–1.51) 
for point prevalence (p = 3.5 × 10−6). This difference was 
not observed by Stead et al., although they assessed the 
effect of type of abstinence using a different approach. The 
explanation for this apparently counter-intuitive finding 
can be seen from the results of the multiple regression 
analysis, which clearly show that there is a significant 
difference between the control group and the treatment 
group  when  comparing  sustained  abstinence  to  point 
prevalence, with the control group showing much lower 
cessation rates when assessed by sustained abstinence. 
This translates into a higher estimate for sustained absti-
nence than that for point prevalence by meta-analysis. 
This example once again demonstrates that the results of 
a meta-analysis cannot be used to assess the effect of a 
confounding factor on cessation rates.
A  final  point  regarding  this  comparison  is  that  the 
heterogeneity observed in the meta-analytic estimates 
can be explained by type of abstinence reported, since 
I2 values for both of these factors were not significant 
(sustained abstinence, p = 0.16 on 71 degrees of freedom; 
point prevalence, p = 0.29 on 31 degrees of freedom). As a 
consequence, it was of interest to determine the pooled 
ORs for smokers of blended cigarettes and flue-cured cig-
arettes, which was not differentiated in the meta-analysis, 
as a function of this variable. As noted above, although 
no heterogeneity had been observed in the pooled OR for 
blended data sets, the pooled OR for flue-cured data sets 
was heterogeneous. When this calculation was carried 
out, no significant heterogeneity was observed in any of 
the pooled ORs with p = 0.32 on 54 degrees of freedom for 
blended and sustained abstinence; p = 0.65 on 28 degrees 
of  freedom  for  blended  and  point  prevalence;  p = 0.15 
on 16 degrees of freedom for flue-cured and sustained 
abstinence;  and  p = 0.31  on  2  degrees  of  freedom  for 
flue-cured and point prevalence. The relevant ORs are 
listed in Table 3, and the close agreement between the 
fixed effects estimate and the random effects estimate 
confirms the lack of heterogeneity. As with the complete 
analysis of the effect of NRT on smoking cessation for 
smokers of blended and flue-cured cigarettes, the pooled 
ORs for blended smokers remained higher than that for 
flue-cured smokers in both subgroups, although the dif-
ferences were not statistically significant.
As indicated, although the pooled OR for smokers of 
blended cigarettes was greater (1.80) than that for smok-
ers  of  flue-cured  cigarettes  (1.61),  the  difference  was 
not statistically significant (p = 0.39). There were also no 
statistical differences for all other potential confounding 
factors that were evaluated in the logistic regression anal-
ysis, including the decade during which a study was con-
ducted, study size, the time period at which abstinence 
was checked (6 months or 1 year), and study quality.
conclusions
The main conclusion resulting from this analysis is that 
there is no evidence that cessation rates for smokers of 
blended cigarettes, which contain a numbers of ingre-
dients, including a mixture of flavorants, are any lower 
than those for smokers of flue-cured cigarettes, which 
contain few ingredients and no flavorants. Despite the 
fact that multiple logistic regression analysis did indeed 
determine that there was a small but statistically signifi-
cant difference in cessation rates that favored smokers 
of blended cigarettes, it would be difficult to consider 
this result as being a real effect. At this time, there is no 
rational explanation that would suggest that addition of 
a number of ingredients to cigarettes would increase the 
ease of smoking cessation. However, all the data are con-
sistent with the conclusion that the presence of ingredi-
ents currently being added to tobacco does not increase 
inherent cigarette addictiveness.
The major strength of this study is that three different 
approaches were utilized to analyze the data, providing 
considerable confidence in the final conclusions. Second, 
the data sets analyzed allow comparison of at least some 
of the results of this study with already published results, 
thereby also supporting the conclusions reached in this 
analysis. However, the choice of these data sets is also a 
weakness of this study. Due to the restriction of the data 
sets to those investigating only the use of NRT, as well as 
the fact that the control group had to be matched to the 
treatment group with the exception of NRT use, there 
were undoubtedly a number of data sets that could have 
been included in the multiple logistic regression analysis 
that were not included. On the other hand, there were 
108  control  data  sets  included  in  the  multiple  logistic 
regression analysis with more than 100,000 subjects. It 
is highly unlikely that inclusion of additional data sets 
would  have  changed  the  conclusions  reached  by  this 
analysis. Another possible limitation of this study is that 
there were a number of other factors that could have con-
tributed to differences in cessation rates; for example, 
methods  of  recruitment  and  study  setting  that  could 
not be evaluated. It should be noted that there could be 
cultural differences that could influence smoking cessa-
tion rates between countries in which cigarettes without 242  E. Sanders et al.
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ingredients are smoked compared to those in which ciga-
rettes with ingredients are smoked. Every attempt was 
made to minimize such cultural differences in that the 
studies that were used were all drawn from developed 
countries with generally similar cultural backgrounds.
This  analysis  also  confirms  a  number  of  other  fac-
tors  of  importance  with  respect  to  smoking  cessation 
that have been previously reported. The results clearly 
demonstrate that NRT is effective, at least in the setting 
of a clinical trial, in increasing the probability of quit-
ting smoking. The pooled ORs for all types of NRT is in 
exact agreement with the Stead et al. review when the 
same meta-analytic methodology is used, even though 
there was not a complete overlap of data sets used in the 
two analyses. Second, this analysis demonstrates that a 
high level of psychological support provides a clearly sig-
nificant benefit with respect to smoking cessation above 
and beyond the effect of NRT. The role that various types 
of  psychological  or  behavioral  support  can  play  with 
respect to smoking cessation has been known for many 
years (Schwartz, 1979), and there have been a number 
of  recent  meta-analyses  that  clearly  demonstrate  this 
(see Schmelzle et al., 2008, for a summary). However, 
this analysis is the first to demonstrate the importance of 
psychological/behavioral support using multiple logistic 
regression  analysis.  Lastly,  the  method  used  to  deter-
mine smoking cessation, sustained abstinence, or point 
prevalence, provides results that are clearly statistically 
distinguishable, and, moreover, this factor is responsible 
for the heterogeneity observed in the various pooled ORs. 
This finding is consistent with the manner in which these 
reporting methods are defined, and data sets included 
in  this  analysis  clearly  demonstrate  that  when  results 
using both methods are presented, the cessation rates 
are invariably higher for reporting by point prevalence 
than by sustained abstinence. However, no multistudy 
analysis has been previously published. Both this analy-
sis and the Stead et al., review used sustained abstinence 
as the default evaluation, and it might be suggested that 
any future studies evaluating smoking cessation use sus-
tained abstinence as the reporting method. It is interest-
ing to note that almost all European studies and studies 
in  flue-cured  countries  used  sustained  abstinence  to 
report results, whereas only about 50% of American stud-
ies used sustained abstinence.
acknowledgments
The  authors  would  like  to  acknowledge  the  efforts  of 
Louis Anthony Cox with respect to conducting the CTA. 
The authors would also like to thank Richard Carchman 
for his helpful comments and discussion.
Declaration of interest
ES is a former employee of PMI and acted as consultants 
on this work for Philip Morris International. RW, RD and 
AU are current employees of Philip Morris International.
References
Abelin T, Buehler A, Müller P, Vesanen K, Imhof PR. 1989. Controlled 
trial of transdermal nicotine patch in tobacco withdrawal. Lancet 
1:7–10.
Ahluwalia  JS,  Okuyemi  K,  Nollen  N,  Choi  WS,  Kaur  H,  Pulvers  K, 
Mayo MS. 2006. The effects of nicotine gum and counseling among 
African American light smokers: a 2 × 2 factorial design. Addiction 
101:883–891.
ASH, 2011. Ash fact sheets. The UK Tobacco Industry. Available at: 
http//www.ash.org.UK/files/documents_ASH123.pdf
Biggs D, de Ville B, Suena E. 1991. A method of choosing multiway 
partitions for classification and decision trees. J Appl Statist, 18: 
49–62.
Binnie VI, McHugh S, Jenkins W, Borland W, Macpherson LM. 2007. 
A randomised controlled trial of a smoking cessation intervention 
delivered  by  dental  hygienists:  a  feasibility  study.  BMC  Oral 
Health 7:5.
Blöndal  T.  1989.  Controlled  trial  of  nicotine  polacrilex  gum  with 
supportive measures. Arch Intern Med 149:1818–1821.
Blöndal T, Franzon M, Westin A. 1997. A double-blind randomized 
trial of nicotine nasal spray as an aid in smoking cessation. Eur 
Respir J 10:1585–1590.
British  Thoracic  Society.  1983.  Comparison  of  four  methods  of 
smoking  withdrawal  in  patients  with  smoking  related  diseases. 
BMJ, 286: 595–597.
Campbell  IA,  Lyons  E,  Prescott  RJ.  1987.  Stopping  smoking.  Do 
nicotine chewing-gum and postal encouragement add to doctors’ 
advice. Practitioner 231:114–117.
Campbell IA, Prescott RJ, Tjeder-Burton SM. 1991. Smoking cessation 
in hospital patients given repeated advice plus nicotine or placebo 
chewing gum. Respir Med 85:155–157.
Campbell  IA,  Prescott  RJ,  Tjeder-Burton  SM.  1996.  Transdermal 
nicotine plus support in patients attending hospital with smoking-
related diseases: a placebo-controlled study. Respir Med 90:47–51.
Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W, Van Vunakis H. 
1996. Behavior therapy and the transdermal nicotine patch: effects 
on cessation outcome, affect, and coping. J Consult Clin Psychol 
64:314–323.
Cooper  TV,  Klesges  RC,  Debon  MW,  Zbikowski  SM,  Johnson  KC, 
Clemens LH. 2005. A placebo controlled randomized trial of the 
effects of phenylpropanolamine and nicotine gum on cessation 
rates  and  postcessation  weight  gain  in  women.  Addict  Behav 
30:61–75.
Dautzenberg  B,  Nides  M,  Kienzler  JL,  Callens  A.  2007. 
Pharmacokinetics, safety and efficacy from randomized controlled 
trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell). BMC 
Clin Pharmacol 7:11.
Dautzenberg B, Peiffer G, Toulouse F, Yvinec MJ, Jacob N, Kienzler J.   
2001.  Randomized  trial  assessment  of  nicotine  lozenge  1 mg,  a 
new oral nicotine replacement therapy. Abstract Book, Society for 
Research on Nicotine and Tobacco Third International Conference, 
Paris, 55.
Davis DL and Nielsen MT. 2007. Tobacco: Production, Chemistry and 
Technology. Oxford, UK: Blackwell Publishing. 
Ehrsam RE, Bühler A, Müller P, Mauli D, Schumacher PM, Howald H, 
Imhof PR. 1991. [Weaning of young smokers using a transdermal 
nicotine patch]. Schweiz Rundsch Med Prax 80:145–150.
European Commission Health & Consumer Protection Directorate, 
2007. Reporting on tobacco product ingredients. Practical Guide. 
European Commission, Brussels.
Fagerström KO. 1982. A comparison of psychological and pharma-
cological treatment in smoking cessation. J Behav Med 5:343–351.
Fagerström KO. 1984. Effects of nicotine chewing gum and follow-up 
appointments in physician-based smoking cessation. Prev Med 
13:517–527.
Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. 
1994. Two studies of the clinical effectiveness of the nicotine patch 
with different counseling treatments. Chest 105:524–533.Cigarette ingredients and addictiveness  243
© 2012 Informa Healthcare USA, Inc. 
Fortmann SP, Killen JD. 1995. Nicotine gum and self-help behavioral 
treatment for smoking relapse prevention: results from a trial 
using  population-based  recruitment.  J  Consult  Clin  Psychol 
63:460–468.
Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner 
B,  Vokonas  PS.  2000.  Effects  of  nicotine  gum  dose  by  level  of 
nicotine dependence. Nicotine Tob Res 2:53–63.
Gilbert JR, Wilson DM, Best JA, Taylor DW, Lindsay EA, Singer J, Willms 
DG.  1989.  Smoking  cessation  in  primary  care.  A  randomized 
controlled  trial  of  nicotine-bearing  chewing  gum.  J  Fam  Pract 
28:49–55.
Glavas  D,  Rumboldt  M,  Rumboldt  Z.  2003a.  Smoking  cessation 
with nicotine replacement therapy among health care workers: 
randomized double-blind study. Croat Med J 44:219–224.
Glavas  D,  Rumboldt  Z.  2003b.  [Smoking  cessation  using  the 
transdermal nicotine system]. Lijec Vjesn 125:8–12.
Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell 
RM,  Keyes  GG,  Nilsson  F,  Hobbs  GR.  2002.  A  comparison  of  a 
nicotine  sublingual  tablet  and  placebo  for  smoking  cessation. 
Nicotine Tob Res 4:441–450.
Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. 1995. Double 
blind  trial  of  repeated  treatment  with  transdermal  nicotine  for 
relapsed smokers. BMJ 311:363–366.
Gross J, Johnson J, Sigler L, Stitzer ML. 1995. Dose effects of nicotine 
gum. Addict Behav 20:371–381.
Hall SM, Tunstall C, Rugg D, Jones RT, Benowitz N. 1985. Nicotine gum 
and  behavioral  treatment  in  smoking  cessation.  J  Consult  Clin 
Psychol 53:256–258.
Hall  SM,  Tunstall  CD,  Ginsberg  D,  Benowitz  NL,  Jones  RT.  1987. 
Nicotine gum and behavioral treatment: a placebo controlled trial. 
J Consult Clin Psychol 55:603–605.
Hand S, Edwards S, Campbell IA, Cannings R. 2002. Controlled trial of 
three weeks nicotine replacement treatment in hospital patients 
also given advice and support. Thorax 57:715–718.
Harackiewicz JM, Blair LW, Sansone C, Epstein JA, Stuchell RN. 1988. 
Nicotine  gum  and  self-help  manuals  in  smoking  cessation:  an 
evaluation in a medical context. Addict Behav 13:319–330.
Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD,  
Nides  MA,  Davidson  M.  1999.  Over-the-counter  nicotine  patch 
therapy for smoking cessation: results from randomized, double-
blind, placebo-controlled, and open label trials. Am J Public Health 
89:1701–1707.
Henningfield JE, Benowitz NL, Connolly GN, Davis RM, Gray N, Myers 
ML, Zeller M. 2004. Reducing tobacco addiction through tobacco 
product regulation. Tob Control 13:132–135.
Higgins  JP,  Thompson  SG,  Deeks  JJ,  Altman  DG.  2003.  Measuring 
inconsistency in meta-analyses. BMJ 327:557–560.
Hilberink  SR,  Jacobs  JE,  Breteler  MH,  de  Vries  H,  Grol  RP.  2011. 
General practice counseling for patients with chronic obstructive 
pulmonary disease to quit smoking: impact after 1 year of two 
complex interventions. Patient Educ Couns 83:120–124.
Hjalmarson  AI.  1984.  Effect  of  nicotine  chewing  gum  in  smoking 
cessation. A randomized, placebo-controlled, double-blind study. 
JAMA 252:2835–2838.
Hjalmarson  A,  Franzon  M,  Westin  A,  Wiklund  O.  1994.  Effect  of 
nicotine nasal spray on smoking cessation. A randomized, placebo-
controlled, double-blind study. Arch Intern Med 154:2567–2572.
Hjalmarson A, Nilsson F, Sjöström L, Wiklund O. 1997. The nicotine 
inhaler in smoking cessation. Arch Intern Med 157:1721–1728.
Hughes  JR,  Gust  SW,  Keenan  RM,  Fenwick  JW,  Healey  ML.  1989. 
Nicotine  vs  placebo  gum  in  general  medical  practice.  JAMA 
261:1300–1305.
Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. 2003. Efficacy 
of nicotine patch in smokers with a history of alcoholism. Alcohol 
Clin Exp Res 27:946–954.
Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC. 1990. Nicotine-
replacement therapy with use of a transdermal nicotine patch—a 
randomized  double-blind  placebo-controlled  trial.  Mayo  Clin 
Proc 65:1529–1537.
Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, 
Lauger GG, Marusic Z, Neese LW, Lundberg TG. 1994. Nicotine 
patch  therapy  for  smoking  cessation  combined  with  physician 
advice and nurse follow-up. One-year outcome and percentage of 
nicotine replacement. JAMA 271:595–600.
Imperial  Cancer  Research  Fund  General  Practice  Group.  1994. 
Randomised trial of nicotine patches in general practice: results at 
one year. BMJ, 308: 1476–1477.
Jamrozik K, Fowler G, Vessey M, Wald N. 1984. Placebo controlled trial 
of nicotine chewing gum in general practice. Br Med J (Clin Res 
Ed) 289:794–797.
Jarvis  MJ,  Raw  M,  Russell  MA,  Feyerabend  C.  1982.  Randomised 
controlled trial of nicotine chewing-gum. Br Med J (Clin Res Ed) 
285:537–540.
Jensen EJ, Schmidt E, Pedersen B, Dahl R. 1991. The effect of nicotine, 
silver  acetate,  and  placebo  chewing  gum  on  the  cessation  of 
smoking. The influence of smoking type and nicotine dependence. 
Int J Addict 26:1223–1231.
Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes 
AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, 
Baker TB. 1999. A controlled trial of sustained-release bupropion, 
a nicotine patch, or both for smoking cessation. N Engl J Med 
340:685–691.
Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele 
BG, Sherman SE, Cleveland M, Antonuccio DO, Antonnucio DO, 
Hartman N, McGovern PG. 1996. The safety of transdermal nicotine 
as an aid to smoking cessation in patients with cardiac disease. N 
Engl J Med 335:1792–1798.
Killen  JD,  Maccoby  N,  Taylor  CB.  1984.  Nicotine  gum  and  self-
regulation training in smoking relapse prevention. Behav Ther, 15: 
234–248.
Killen JD, Fortmann SP, Newman B, Varady A. 1990. Evaluation of a 
treatment  approach  combining  nicotine  gum  with  self-guided 
behavioral treatments for smoking relapse prevention. J Consult 
Clin Psychol 58:85–92.
Killen JD, Fortmann SP, Davis L, Varady A. 1997. Nicotine patch and 
self-help  video  for  cigarette  smoking  cessation.  J  Consult  Clin 
Psychol 65:663–672.
Kinnunen T, Korhonen T, Garvey AJ. 2008. Role of nicotine gum and 
pretreatment depressive symptoms in smoking cessation: twelve-
month  results  of  a  randomized  placebo  controlled  trial.  Int  J 
Psychiatry Med 38:373–389.
Kornitzer  M,  Boutsen  M,  Dramaix  M,  Thijs  J,  Gustavsson  G.  1995. 
Combined use of nicotine patch and gum in smoking cessation: a 
placebo-controlled clinical trial. Prev Med 24:41–47.
Kralikova E, Kozak J, Rasmussen T, Cort N. 2002. The clinical benefits 
of NRT-supported smoking reduction. Nicotine Tob Res, 4, 243.
Kralikova  E,  Kozak  JT,  Rasmussen  T,  Gustavsson  G,  Le  Houezec  J. 
2009. Smoking cessation or reduction with nicotine replacement 
therapy: a placebo-controlled double blind trial with nicotine gum 
and inhaler. BMC Public Health 9:433.
Lee  PN,  Forey  BA,  Fry  JS,  Hamling  JS,  Hamling  JF,  Sanders  EB, 
Carchman RA. 2009. Does use of flue-cured rather than blended 
cigarettes  affect  international  variation  in  mortality  from  lung 
cancer and COPD? Inhal Toxicol 21:404–430.
Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP. 1996. 
Efficacy of the nicotine inhaler as an adjunct to smoking cessation. 
Am J Health Behav, 20: 364–371.
Lewis  SF,  Piasecki  TM,  Fiore  MC,  Anderson  JE,  Baker  TB.  1998. 
Transdermal  nicotine  replacement  for  hospitalized  patients:  a 
randomized clinical trial. Prev Med 27:296–303.
Malcolm RE, Sillett RW, Turner JA, Ball KP. 1980. The use of nicotine 
chewing gum as an aid to stopping smoking. Psychopharmacology 
(Berl) 70:295–296.
McGovern PG, Lando HA. 1992. An assessment of nicotine gum as an 
adjunct to freedom from smoking cessation clinics. Addict Behav 
17:137–147.
Molyneux A, Lewis S, Leivers U, Anderton A, Antoniak M, Brackenridge 
A, Nilsson F, McNeill A, West R, Moxham J, Britton J. 2003. Clinical 244  E. Sanders et al.
  Inhalation Toxicology
trial  comparing  nicotine  replacement  therapy  (NRT)  plus  brief 
counselling, brief counselling alone, and minimal intervention on 
smoking cessation in hospital inpatients. Thorax 58:484–488.
Moolchan  ET,  Robinson  ML,  Ernst  M,  Cadet  JL,  Pickworth  WB, 
Heishman SJ, Schroeder JR. 2005. Safety and efficacy of the nicotine 
patch and gum for the treatment of adolescent tobacco addiction. 
Pediatrics 115:e407–e414.
Müller P, Abelin T, Ehrsam R, Imhof P, Howald H, Mauli D. 1990. 
The use of transdermal nicotine in smoking cessation. Lung 168 
Suppl:445–453.
Niaura R, Abrams DB, Shadel WG, Rohsenow DJ, Monti PM, Sirota AD. 
1999. Cue exposure treatment for smoking relapse prevention: a 
controlled clinical trial. Addiction 94:685–695.
Okuyemi  KS,  James  AS,  Mayo  MS,  Nollen  N,  Catley  D,  Choi  WS, 
Ahluwalia  JS.  2007.  Pathways  to  health:  a  cluster  randomized 
trial of nicotine gum and motivational interviewing for smoking 
cessation in low-income housing. Health Educ Behav, 34: 43–54.
Oncken C, Cooney J, Feinn R, Lando H, Kranzler HR. 2007. Transdermal 
nicotine for smoking cessation in postmenopausal women. Addict 
Behav 32:296–309.
Oncken  C,  Dornelas  E,  Greene  J,  Sankey  H,  Glasmann  A,  Feinn 
R,  Kranzler  HR.  2008.  Nicotine  gum  for  pregnant  smokers:  a 
randomized controlled trial. Obstet Gynecol 112:859–867.
Paoletti  P,  Fornai  E,  Maggiorelli  F,  Puntoni  R,  Viegi  G,  Carrozzi  L, 
Corlando A, Gustavsson G, Säwe U, Giuntini C. 1996. Importance   
of baseline cotinine plasma values in smoking cessation: results 
from a  double-blind study with nicotine patch.  Eur Respir J 9: 
643–651.
Pirie PL, McBride CM, Hellerstedt W, Jeffery RW, Hatsukami D, Allen 
S, Lando H. 1992. Smoking cessation in women concerned about 
weight. Am J Public Health 82:1238–1243.
Petitti DB. 2000. Meta-analysis, decision analysis, and cost effective 
analysis  methods  for  quantitative  synthesis  in  medicine.  In 
Monographs in epidemiology and biostatistics, Second edition, 
New York: Oxford University Press.
Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, Pletsch PK, 
Peterson BL, Heine RP, Brouwer RJ, Fish L, Myers ER. 2007. Nicotine 
replacement  and  behavioral  therapy  for  smoking  cessation  in 
pregnancy. Am J Prev Med 33:297–305.
Prapavessis  H,  Cameron  L,  Baldi  JC,  Robinson  S,  Borrie  K,   
Harper  T,  Grove  JR.  2007.  The  effects  of  exercise  and  nicotine 
replacement therapy on smoking rates in women. Addict Behav 
32:1416–1432.
Puska  P,  Oorhonen  HJ,  Vartianen  E,  Urjanheimo  EL,  Gustavsson 
G,  Westin  A.  1995.  Combined  use  of  nicotine  patch  and  gum 
compared with gum alone in smoking cessation: a clinical trial in 
North Karelia. Tob Control, 4: 231–235.
Quílez  García  C,  Hernando  Arizaleta  L,  Rubio  Díaz  A,  Granero 
Fernández EJ, Vila Coll MA, Estruch Riba J. 1989. [Double-blind 
study of the efficacy of nicotine chewing gum for smoking cessation 
in the primary care setting]. Aten Primaria 6:719–726.
Rennard  SI,  Glover  ED,  Leischow  S,  Daughton  DM,  Glover  PN, 
Muramoto M, Franzon M, Danielsson T, Landfeldt B, Westin A. 
2006.  Efficacy  of  the  nicotine  inhaler  in  smoking  reduction:  A 
double-blind, randomized trial. Nicotine Tob Res 8:555–564.
Richmond RL, Makinson RJ, Kehoe LA, Giugni AA, Webster IW. 1993. 
One-year  evaluation  of  three  smoking  cessation  interventions 
administered by general practitioners. Addict Behav 18:187–199.
Richmond RL, Harris K, de Almeida Neto A. 1994. The transdermal 
nicotine patch: results of a randomised placebo-controlled trial. 
Med J Aust 161:130–135.
Russell MA, Merriman R, Stapleton J, Taylor W. 1983. Effect of nicotine 
chewing gum as an adjunct to general practitioner’s advice against 
smoking. Br Med J (Clin Res Ed) 287:1782–1785.
Sachs  DP,  Säwe  U,  Leischow  SJ.  1993.  Effectiveness  of  a  16-hour 
transdermal nicotine patch in a medical practice setting, without 
intensive group counseling. Arch Intern Med 153:1881–1890.
Salvador Llivina T, Marín Tuyà D, González Quintana J, Iniesta Torres 
C,  Castellví  Barrera  E,  Muriana  Sáez  C,  Agustí  Vidal  A.  1988. 
[Treatment of smoking: efficacy of the use of nicotine chewing 
gum. Double-blind study]. Med Clin (Barc) 90:646–650.
SCENIHR (Scientific Committee on Emerging and Newly Identified 
Health Risks). 2010. Addictiveness and Attractiveness of Tobacco 
Additives, November 2010.
Schmelzle J, Rosser WW, Birtwhistle R. 2008. Update on pharmacologic 
and nonpharmacologic therapies for smoking cessation. Can Fam 
Physician 54:994–999.
Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger 
A. 1983. Nicotine gum in smoking cessation: a placebo-controlled, 
double-blind trial. Addict Behav 8:253–261.
Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, 
Steinberg C. 1995. Efficacy of a nicotine nasal spray in smoking 
cessation:  a  placebo-controlled,  double-blind  trial.  Addiction 
90:1671–1682.
Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. 
1996. Efficacy of a nicotine inhaler in smoking cessation: a double-
blind, placebo-controlled trial. Addiction 91:1293–1306.
Schwartz  JL.  1979.  Review  and  evaluation  of  methods  of  smoking 
cessation, 1969-77. Summary of a monograph. Public Health Rep 
94:558–563.
Segnan N, Ponti A, Battista RN, Senore C, Rosso S, Shapiro SH, Aimar 
D. 1991. A randomized trial of smoking cessation interventions in 
general practice in Italy. Cancer Causes Control 2:239–246.
Select Committee on Health of the UK Houses of Parliament. 2000. 
Second  report  of  the  Select  Committee  on  Health  of  the  UK 
Houses of Parliament. The tobacco industry and the health risks of 
smoking. Appendices to the Minutes of Evidence.
Shiffman S, Ferguson SG, Strahs KR. 2009. Quitting by gradual smoking 
reduction using nicotine gum: a randomized controlled trial. Am J 
Prev Med 36:96–104.e1.
Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, 
Sawe U, Wiseman D. 1995. Dose effects and predictors of outcome 
in a randomized trial of transdermal nicotine patches in general 
practice. Addiction 90:31–42.
Stead  JF,  Perera  R,  Bullen  C,  Mant  D,  Lancaster  T.  2008.  Nicotine 
replacement  therapy  for  smoking  cessation  (review).  Cochrane 
Database Syst Rev, 1: CD000146.
Stookey GK, Katz BP, Olson BL, Drook CA, Cohen SJ. 1987. Evaluation 
of biochemical validation measures in determination of smoking 
status. J Dent Res 66:1597–1601.
Strobl  C,  Malley  J,  Tutz  G.  2009.  An  introduction  to  recursive 
partitioning:  rationale,  application,  and  characteristics  of 
classification and regression trees, bagging, and random forests. 
Psychol Methods 14:323–348.
Sutherland G, Stapleton JA, Russell MA, Jarvis MJ, Hajek P, Belcher M, 
Feyerabend C. 1992. Randomised controlled trial of nasal nicotine 
spray in smoking cessation. Lancet 340:324–329.
Tønnesen P, Fryd V, Hansen M, Helsted J, Gunnersen AB, Forchammer 
H, Stockner M. 1988. Effect of nicotine chewing gum in combination 
with group counseling on the cessation of smoking. N Engl J Med 
318:15–18.
Tønnesen P, Nørregaard J, Simonsen K, Säwe U. 1991. A double-blind 
trial of a 16-hour transdermal nicotine patch in smoking cessation. 
N Engl J Med 325:311–315.
Tønnesen P, Nørregaard J, Mikkelsen K, Jørgensen S, Nilsson F. 1993. 
A double-blind trial of a nicotine inhaler for smoking cessation. 
JAMA 269:1268–1271.
Tønnesen P, Mikkelsen K, Bremann L. 2006. Nurse-conducted smoking 
cessation in patients with COPD using nicotine sublingual tablets 
and behavioral support. Chest 130:334–342.
Transdermal  Nicotine  Study  Group.  1991.  Transdermal  nicotine 
for  smoking  cessation.  Six-month  results  from  two  multicenter 
controlled clinical trials. JAMA, 266: 3133–3138.
U.S. Department of Health and Human Services. 2010. How Tobacco 
Smoke  Causes  Disease:  The  Biology  and  Behavioral  Basis  for 
Smoking-Attributable Disease: A Report of the Surgeon General. 
Atlanta,  GA:  U.S.  Department  of  Health  and  Human  Services, 
Centers for Disease Control and Prevention, National Center for Cigarette ingredients and addictiveness  245
© 2012 Informa Healthcare USA, Inc. 
Chronic  Disease  Prevention  and  Health  Promotion,  Office  on 
Smoking and Health.
U.S. Department of Health and Human Services. 2003. NCI Smoking 
and Control Monograph 15. Those Who Continue to Smoke. Is 
Achieving  Abstinence  Harder  and  Do  We  Need  to  Change  Our 
Interventions?  National  Institutes  of  Health,  National  Cancer 
Institute. Chapter 1, p. 16.
Wallace BC, Schmid CH, Lau J, Trikalinos TA. 2009. Meta-Analyst: 
software for meta-analysis of binary, continuous and diagnostic 
data. BMC Med Res Methodol 9:80.
Wallström M, Nilsson F, Hirsch JM. 2000. A randomized, double-blind, 
placebo-controlled  clinical  evaluation  of  a  nicotine  sublingual 
tablet in smoking cessation. Addiction 95:1161–1171.
Westman EC, Levin ED, Rose JE. 1993. The nicotine patch in smoking 
cessation.  A  randomized  trial  with  telephone  counseling.  Arch 
Intern Med 153:1917–1923.
Wewers ME, Ferketich AK, Harness J, Paskett ED. 2009. Effectiveness 
of  a  nurse-managed,  lay-led  tobacco  cessation  intervention 
among ohio appalachian women. Cancer Epidemiol Biomarkers 
Prev 18:3451–3458.